Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes
AuthorBlombery, P; Fox, LC; Ryland, GL; Thompson, ER; Lickiss, J; McBean, M; Yerneni, S; Hughes, D; Greenway, A; Mechinaud, F; ...
Source TitleHaematologica: the hematology journal
PublisherFERRATA STORTI FOUNDATION
University of Melbourne Author/sGaff, Clara; Szer, Jeffrey; Thompson, Ella; Ritchie, David; Blombery, Piers; Ryland, Georgina; Martyn, Melissa; Fox, Lucy
Medicine and Radiology
Sir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsBlombery, P., Fox, L. C., Ryland, G. L., Thompson, E. R., Lickiss, J., McBean, M., Yerneni, S., Hughes, D., Greenway, A., Mechinaud, F., Wood, E. M., Lieschke, G. J., Szer, J., Barbaro, P., Roy, J., Wight, J., Lynch, E., Martyn, M., Gaff, C. & Ritchie, D. (2021). Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. HAEMATOLOGICA, 106 (1), pp.64-73. https://doi.org/10.3324/haematol.2019.237693.
Access StatusAccess this item via the Open Access location
Open Access URLhttp://doi.org/10.3324/haematol.2019.237693
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776333
Bone marrow failure (BMF) related to hypoplasia of hematopoietic elements in the bone marrow is a heterogeneous clinical entity with a broad differential diagnosis including both inherited and acquired causes. Accurate diagnostic categorization is critical to optimal patient care and detection of genomic variants in these patients may provide this important diagnostic and prognostic information. We performed real-time, accredited (ISO15189) comprehensive genomic characterization including targeted sequencing and whole exome sequencing in 115 patients with BMF syndrome (median age 24 years, range 3 months - 81 years). In patients with clinical diagnoses of inherited BMF syndromes, acquired BMF syndromes or clinically unclassifiable BMF we detected variants in 52% (12/23), 53% (25/47) and 56% (25/45) respectively. Genomic characterization resulted in a change of diagnosis in 30/115 (26%) including the identification of germline causes for 3/47 and 16/45 cases with pre-test diagnoses of acquired and clinically unclassifiable BMF respectively. The observed clinical impact of accurate diagnostic categorization included choice to perform allogeneic stem cell transplantation, disease-specific targeted treatments, identification of at-risk family members and influence of sibling allogeneic stem cell donor choice. Multiple novel pathogenic variants and copy number changes were identified in our cohort including in TERT, FANCA, RPS7 and SAMD9. Whole exome sequence analysis facilitated the identification of variants in two genes not typically associated with a primary clinical manifestation of BMF but also demonstrated reduced sensitivity for detecting low level acquired variants. In conclusion, genomic characterization can improve diagnostic categorization of patients presenting with hypoplastic BMF syndromes and should be routinely performed in this group of patients.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References